Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Placebo Controlled, 4-group Parallel Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.

NCT03723798 is registered in ClinicalTrials.gov with Samjin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03723798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03723798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Placebo Controlled, 4-group Parallel Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
Lead sponsor
Samjin Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2017
Completion date
October 8, 2018
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye syndrome